Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: Ophthalmology. 2021 Apr 20;128(12):1699–1707. doi: 10.1016/j.ophtha.2021.04.017

Figure 2.

Figure 2.

Recombinant zoster vaccine effectiveness against HZO by age, sex, race/ethnicity and history of ZVL from 2018 to 2019

CI = Confidence interval.

ZVL = Zoster vaccine live.

a Values are reported as %.

b Vaccine effectiveness was adjusted using inverse probability weighting for age, sex, race, region, prior zoster vaccine live, antiviral use, healthcare utilization, insurance type, and Charlson comorbidity index.

c Vaccine effectiveness was 100% in the subgroup, but the confidence interval could not be calculated because there were no cases of HZO in the vaccinated cohort.

d The unknown race/ethnicity category includes individuals with either unknown or missing race/ethnicity.